Gilead Sciences (NASDAQ:GILD) has initiated two
Phase 3 clinical trials in the UK evaluating remdesivir in
moderately-to-severely ill COVID-19 patients. 15 sites will be initially
involved.
https://seekingalpha.com/news/3557138-gilead-sciences-launches-two-remdesivir-studies-in-uk
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.